• Binding services agreement executed with Temasek Innovation Holdings Pte Ltd (TPIH)
• Commencement of two-stage, cell-based efficacy testing program for Project Giddy-Up
• Seaweed-based formulation positioned for male vitality, anti-fatigue, stress recovery and sleep/wellness support

BPH Global Ltd (ASX: BP8), a leading commercial seaweed supply and export company, has executed a services agreement with Temasek Innovation Holdings Pte Ltd (TPIH), an operating entity of Temasek Polytechnic, Singapore, for the provision of efficacy testing services in relation to Project Giddy-Up. This milestone builds on the company's previous announcements confirming the finalisation of the proprietary formulation and agreement in principle for TPIH to undertake a structured testing program. The program will involve a two-stage, in-vitro, cell-based testing regime designed to evaluate the formulation's biological activity across pathways associated with male vitality, circulation and hormonal support. This includes assays to assess PDE-5 inhibition, nitric oxide and cGMP pathway analysis, and testosterone production assessment. The testing will also include ICP-MS analysis to assess the presence of heavy metals, supporting product safety and quality validation. The agreement includes defined deliverables, IP ownership and a structured timeline through to October 2026. With the agreement now executed, the company will commence laboratory testing activities with TPIH, progress evaluation of formulation efficacy and optimisation opportunities, and advance development milestones aligned with its regulatory strategy to list Project Giddy-Up on the Australian Register of Therapeutic Goods (ARTG) as a TGA-listed complementary medicine (AUST L).